These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 35941070)

  • 1. SOHO State of the Art Updates and Next Questions | Novel Approaches to Pediatric T-cell ALL and T-Lymphoblastic Lymphoma.
    Summers RJ; Teachey DT
    Clin Lymphoma Myeloma Leuk; 2022 Oct; 22(10):718-725. PubMed ID: 35941070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How I treat newly diagnosed and refractory T-cell acute lymphoblastic lymphoma in children and young adults.
    Si Lim SJ; Ford JB; Hermiston ML
    Blood; 2023 Jun; 141(25):3019-3030. PubMed ID: 37018730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Update on Clinical Trials and Potential Therapeutic Strategies in T-Cell Acute Lymphoblastic Leukemia.
    Patel J; Gao X; Wang H
    Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-CCR9 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia.
    Maciocia PM; Wawrzyniecka PA; Maciocia NC; Burley A; Karpanasamy T; Devereaux S; Hoekx M; O'Connor D; Leon T; Rapoz-D'Silva T; Pocock R; Rahman S; Gritti G; Yánez DC; Ross S; Crompton T; Williams O; Lee L; Pule MA; Mansour MR
    Blood; 2022 Jul; 140(1):25-37. PubMed ID: 35507686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Facts and Challenges in Immunotherapy for T-Cell Acute Lymphoblastic Leukemia.
    Bayón-Calderón F; Toribio ML; González-García S
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33081391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relapsed/Refractory T- Acute Lymphoblastic Leukemia - Current Options and Future Directions.
    Jeha S
    Indian J Pediatr; 2024 Feb; 91(2):168-175. PubMed ID: 37642889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myeloid lineage switch following CD7-targeted chimeric antigen receptor T-cell therapy in relapsed/refractory T-cell acute lymphoblastic leukemia.
    Aldoss I; Tizro P; Bedi D; Mangan JK; Clark MC; Spencer D; Song JY; Cherian S; Pillai R; Kim Y; Mahajan N; Gendzekhadze K; James M; Jacobs K; Davidson-Moncada J; Forman SJ; Wang HY; Afkhami M
    Haematologica; 2023 Dec; 108(12):3511-3516. PubMed ID: 37470155
    [No Abstract]   [Full Text] [Related]  

  • 8. Nelarabine, etoposide, and cyclophosphamide in relapsed pediatric T-acute lymphoblastic leukemia and T-lymphoblastic lymphoma (study T2008-002 NECTAR).
    Whitlock JA; Malvar J; Dalla-Pozza L; Goldberg JM; Silverman LB; Ziegler DS; Attarbaschi A; Brown PA; Gardner RA; Gaynon PS; Hutchinson R; Huynh VT; Jeha S; Marcus L; Messinger Y; Schultz KR; Cassar J; Locatelli F; Zwaan CM; Wood BL; Sposto R; Gore L
    Pediatr Blood Cancer; 2022 Nov; 69(11):e29901. PubMed ID: 35989458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigational treatment options in phase I and phase II trials for relapsed or refractory acute lymphoblastic leukemia in pediatric patients.
    Asare JM; Rabik CA; Muller B; Brown PA; Cooper S
    Expert Opin Investig Drugs; 2021 Jun; 30(6):611-620. PubMed ID: 33896328
    [No Abstract]   [Full Text] [Related]  

  • 10. Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma.
    Teachey DT; Devidas M; Wood BL; Chen Z; Hayashi RJ; Hermiston ML; Annett RD; Archer JH; Asselin BL; August KJ; Cho SY; Dunsmore KP; Fisher BT; Freedman JL; Galardy PJ; Harker-Murray P; Horton TM; Jaju AI; Lam A; Messinger YH; Miles RR; Okada M; Patel SI; Schafer ES; Schechter T; Singh N; Steele AC; Sulis ML; Vargas SL; Winter SS; Wood C; Zweidler-McKay P; Bollard CM; Loh ML; Hunger SP; Raetz EA
    J Clin Oncol; 2022 Jul; 40(19):2106-2118. PubMed ID: 35271306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted therapy and immunotherapy for T cell acute lymphoblastic leukemia/lymphoma.
    Huang YH; Wan CL; Dai HP; Xue SL
    Ann Hematol; 2023 Aug; 102(8):2001-2013. PubMed ID: 37227492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnosis and management of lymphoblastic lymphoma in children, adolescents and young adults.
    Temple WC; Mueller S; Hermiston ML; Burkhardt B
    Best Pract Res Clin Haematol; 2023 Mar; 36(1):101449. PubMed ID: 36907639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How to Combine the Two Landmark Treatment Methods-Allogeneic Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Together to Cure High-Risk B Cell Acute Lymphoblastic Leukemia?
    Zhang M; Huang H
    Front Immunol; 2020; 11():611710. PubMed ID: 33384696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How I treat adults with advanced acute lymphoblastic leukemia eligible for CD19-targeted immunotherapy.
    Aldoss I; Forman SJ
    Blood; 2020 Mar; 135(11):804-813. PubMed ID: 31899793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A review of CD19-targeted immunotherapies for relapsed or refractory acute lymphoblastic leukemia.
    DasGupta RK; Marini BL; Rudoni J; Perissinotti AJ
    J Oncol Pharm Pract; 2018 Sep; 24(6):453-467. PubMed ID: 28583018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bortezomib Is Effective in the Treatment of T Lymphoblastic Leukaemia by Inducing DNA Damage, WEE1 Downregulation, and Mitotic Catastrophe.
    Din RU; Jiao A; Qiu Y; Mohan AAM; Yuen KC; Wong HT; Wan TM; Wong PO; Sin CF
    Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37834095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T-cell acute lymphoblastic leukemia: promising experimental drugs in clinical development.
    Thomas X
    Expert Opin Investig Drugs; 2023 Jan; 32(1):37-52. PubMed ID: 36541671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-Effectiveness of KTE-X19 for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in the United States.
    Shah BD; Smith NJ; Feng C; Jeyakumar S; Castaigne JG; Faghmous I; Masouleh BK; Malone DC; Bishop MR
    Adv Ther; 2022 Aug; 39(8):3678-3695. PubMed ID: 35727476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pediatric-Like Acute Lymphoblastic Leukemia Therapy in Adults With Lymphoblastic Lymphoma: The GRAALL-LYSA LL03 Study.
    Lepretre S; Touzart A; Vermeulin T; Picquenot JM; Tanguy-Schmidt A; Salles G; Lamy T; Béné MC; Raffoux E; Huguet F; Chevallier P; Bologna S; Bouabdallah R; Benichou J; Brière J; Moreau A; Tallon-Simon V; Seris S; Graux C; Asnafi V; Ifrah N; Macintyre E; Dombret H
    J Clin Oncol; 2016 Feb; 34(6):572-80. PubMed ID: 26644537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The European Medicines Agency Review of Kymriah (Tisagenlecleucel) for the Treatment of Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma.
    Ali S; Kjeken R; Niederlaender C; Markey G; Saunders TS; Opsata M; Moltu K; Bremnes B; Grønevik E; Muusse M; Håkonsen GD; Skibeli V; Kalland ME; Wang I; Buajordet I; Urbaniak A; Johnston J; Rantell K; Kerwash E; Schuessler-Lenz M; Salmonson T; Bergh J; Gisselbrecht C; Tzogani K; Papadouli I; Pignatti F
    Oncologist; 2020 Feb; 25(2):e321-e327. PubMed ID: 32043764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.